Brain-targeted delivery of estradiol: Therapeutic potential and results obtained with a chemical delivery system approach

American Journal of Drug Delivery

Volumn 4, Issue 3, 2006, Pages 161-175

  Bodor, Nicholas ^a   Buchwald, Peter ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b IVAX Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PROGESTERONE; SILDENAFIL;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN; CANCER RISK; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DEMENTIA; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; THERAPY EFFECT;

EID: 33748374488     PISSN: 11759038     EISSN: 11759038     Source Type: Journal    
DOI: 10.2165/00137696-200604030-00004     Document Type: Review

References (179)

1. Williams CL, Stancel GM. Estrogens and progestins. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 1411-40
2. Kaplan NM. Cardiovascular complications of oral contraceptives. Annu Rev Med 1978; 29: 31-40
3. Fotherby K. Oral contraceptives, lipids and cardiovascular disease. Contraception 1985; 31: 367-94
4. Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995; 173: 982-9
5. Yager JD, Liehr JG. Molecular mechanism of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996; 36: 203-32
6. Beral V, Banks E, Reeves G, et al. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999; 4: 191-210
7. Wells G, Herrington DM. The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain? Drugs Aging 1999; 15: 419-22
8. Meade TW, Vickers MR. HRT and cardiovascular disease. J Epidemiol Biostat 1999; 4: 165-90
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
10. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839-54
11. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12
12. Manson JA, Bassuk S, Harman SM, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006; 13: 139-47
13. MacLennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause 2006; 13: 28-36
14. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004; 292: 1581-7
15. Aldridge S. Magic molecules: how drugs work. Cambridge: Cambridge University Press, 1998
16. Rabin R. Rethinking hormones, again. NY Times 2006 Jan 31 [online]. Available from URL: http://query.nytimes.com/gst/fullpage.html?.sec= health&res= 9907EEDA1E3FF932A05752C0A9609C8B63 [Accessed 2006 May 22]
17. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353: 571-80
18. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999; 20: 279-307
19. Cyr M, Calon F, Morissette M, et al. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr Pharm Des 2000; 6: 1287-312
20. Shepherd JE. Effects of estrogen on congnition mood, and degenerative brain diseases. J Am Pharm Assoc 2001; 41: 221-8
21. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003; 24: 133-51
22. Sharpe RM. The roles of oestrogen in the male. Trends Endocrinol Metab 1998; 9: 371-7
23. Faustini-Fustini M, Rochira V, Carani C. Oestrogen deficiency in men: where are we today? Eur J Endocrinol 1999; 140: 111-29
24. Nilsson S, Gustafsson JA. Biological role of estrogen and estrogen receptors. Crit Rev Biochem Mol Biol 2002; 37 (1): 1-28
25. Creutz LM, Kritzer MF. Estrogen receptor-β immunoreactivity in the midbrain of adult rats: regional, subregional, and cellular localization in the A10, A9, and A8 dopamine cell groups. J Comp Neurol 2002; 446: 288-300
26. Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol 1993; 336: 293-306
27. Lustig RH. Sex hormone modulation of neural development in vitro. Horm Behav 1994; 28: 383-95
28. Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 1997; 48 (5): S27-35
29. Prange-Kiel J, Rune GM. Direct and indirect effects of estrogen on rat hippocampus. Neuroscience 2006; 138: 765-72
30. Toran-Allerand CD, Singh M, Setalo G. Novel mechanisms of estrogen action in the brain: new players in an old story. Front Neuroendocrinol 1999; 20: 97-121
31. Wickelgren I. Estrogen stakes claim to cognition. Science 1997; 276: 675-8
32. McEwen BS. Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001; 91: 2785-801
33. Sawada H, Ibi M, Kihara T, et al. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J Neurosci Res 1998; 54: 707-19
34. Svensson A-L, Nordberg A. Beta-estradiol attenuate amyloid beta-peptide toxicity via nicotinic receptors. NeuroReport 1999; 10: 3485-9
35. Moosmann B, Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci U S A 1999; 96: 8867-72
36. Behl C, Manthey D. Neuroprotective activities of estrogen: an update. J Neurocytol 2000; 29: 351-8
37. Beyer C, Pawlak J, Karolczak M. Membrane receptors for oestrogen in the brain. J Neurochem 2003; 87: 545-50
38. Upton GV. Therapeutic considerations in the management of the climacteric. J Reprod Med 1984; 29: 71-9
39. Maggi A, Perez J. Role of female gonadal hormones in the CNS: clinical and experimental aspects. Life Sci 1985; 37: 893-906
40. García-Segura LM, Chowen JA, Párducz A, et al. Gonadal hormones as promoters of structural synaptic plasticity: cellular mechanisms. Progr Neurobiol 1994; 44: 279-307
41. Ohkura T, Isse K, Akazawa K, et al. Evaluation of estrogen-treatment in female-patients with dementia of the Alzheimer-type. Endocr J 1994; 41: 361-71
42. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 346: 429-32
43. Jacobs DM, Tang M-X, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998; 50: 368-73
44. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279: 688-95
45. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999; 24: 657-77
46. Costa MM, Reus VI, Wolkowitz OM, et al. Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biol Psychiatry 1999; 46: 182-8
47. Carlson LE, Sherwin BB. Higher levels of plasma estradiol and testosterone in healthy elderly men compared with age-matched women may protect aspects of explicit memory. Menopause 2000; 7: 168-77
48. Naftolin F. Brain aromatization of androgens. J Reprod Med 1994 Apr; 39 (4): 257-61
49. Rahimy MH, Simpkins JW, Bodor N. Tissue distribution of a brain-enhanced chemical delivery system for estradiol. Drug Des Deliv 1990; 6: 29-40
50. MacLennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; (4): CD002978
51. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999; 181: 71-9
52. von Holst T, Salbach B. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints. Maturitas 2000; 34: 143-53
53. Gerber GS, Zagaja GP, Ray PS, et al. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000; 55: 97-101
54. Naessen T, Lindmark B, Larsen HC. Better postural balance in elderly women receiving estrogens. Am J Obstet Gynecol 1997; 177: 412-6
55. Goebel JA, Birge SJ, Price SC, et al. Estrogen replacement therapy and postural stability in the elderly. Am J Otol 1995; 16: 470-4
56. Lindmark B, Lagerstrom C, Naessen T, et al. Performance in functional balance tests during menopausal hormone replacement: a double-blind placebo-controlled study. Physiother Res Int 1999; 4: 43-54
57. Shepherd JE. Therapeutic options in female sexual dysfunction. J Am Pharm Assoc 2002; 42: 479-88
58. Pfaff D, Frohlich J, Morgan M. Hormonal and genetic influences on arousal: sexual and otherwise. Trends Neurosci 2002; 25: 45-50
59. Zehr JL, Maestripieri D, Wallen K. Estradiol increases female sexual initiation independent of male responsiveness in rhesus monkeys. Horm Behav 1998; 33: 95-103
60. Dennerstein L, Randolph J, Taffe J, et al. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002; 77 Suppl. 4: S42-S8
61. Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol 2003; 188: 286-93
62. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-44
63. Tapfer MK, Sebestyen L, Kurucz I, et al. New evidence for the selective, long-lasting central effects of the brain-targeted estradiol, Estredox. Pharmacol Biochem Behav 2004; 77: 423-9
64. Pfaff D. Nature of sex hormone effects on rat sex behavior: specificity of effects and individual patterns of response. J Comp Physiol Psychol 1970; 73: 349-58
65. Sodersten P. Estrogen-activated sexual behavior in male rats. Horm Behav 1973; 4: 247-56
66. Simpson ER, Davis SR. Another role highlighted for estrogens in the male: sexual behavior. Proc Natl Acad Sci U S A 2000; 97: 14038-40
67. Ogawa S, Chester AE, Hewitt SC, et al. Abolition of male sexual behaviors in mice lacking estrogen receptors α and β (αβERKO). Proc Natl Acad Sci U S A 2000; 97: 14737-41
68. Honda S-I, Harada N, Ito S, et al. Disruption of sexual behavior in male aromatase-deficient mice lacking exons 1 and 2 of the cyp19 gene. Biochem Biophys Res Commun 1998; 252: 445-9
69. Carani C, Rochira V, Faustini-Fustini M, et al. Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clin Endocrinol (Oxf) 1999; 51: 517-24
70. Anderson WR, Simpkins JW, Brewster ME, et al. Evidence for the reestablishment of copulatory behavior in castrated male rats with a brain-enhanced estradiol-chemical delivery system. Pharmacol Biochem Behav 1987; 27: 265-71
71. Bodor N, Buchwald P. Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease. Drug Discov Today 2002; 7: 766-74
72. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999; 341: 1670-9
73. Selkoe DJ. Aging brain, aging mind. Sci Am 1992; 267 (3): 135-42
74. Gopinath L. Outsmarting Alzheimer's disease. Chem Br 1998; 34 (5): 38-40
75. Zhang JY. Apoptosis-based anticancer drugs. Nat Rev Drug Discov 2002; 1: 101-2
76. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA 2000; 283: 1007-15
77. Di Carlo A, Baldereschi M, Amaducci L, et al. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. J Am Geriatr Soc 2002; 50: 41-8
78. Halbreich U, Lumley LA, Palter S, et al. Possible acceleration of age effects on cognition following menopause. J Psychiatr Res 1995; 29: 153-63
79. Kimura D. Sex hormones influence human cognitive pattern. Neuro Endocrinol Lett 2002; 23: 67-77
80. Kimura D. Sex differences in the brain. Sci Am 2002; 12: 32-7
81. Ridley M. The red queen: sex and the evolution of human nature. New York: Macmillan, 1993
82. Christiansen K. Sex hormone-related variations of cognitive performance in !Kung San hunter-gatherers of Namibia. Neuropsychobiology 1993; 27: 97-107
83. van Goozen SHM, Cohen-Kettenis PT, Gooren LJG, et al. Gender differences in behaviour: activating effects of cross-sex hormones. Psychoneuroendocrinology 1995; 20: 343-63
84. Slabbekoorn D, van Goozen SHM, Megens J, et al. Activating effects of cross-sex hormones on cognitive functioning: a study of short-term and long-term hormone effects in transsexuals. Psychoneuroendocrinology 1999; 24: 423-47
85. Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999; 84: 3681-5
86. Hampson E. Variations in sex-related cognitive abilities across the menstrual cycle. Brain Cogn 1990; 14: 26-43
87. Hausmann M, Slabbekoorn D, Van Goozen SHM, et al. Sex hormones affect spatial abilities during the menstrual cycle. Behav Neurosci 2000; 114: 1245-50
88. Maki PM, Rich JB, Rosenbaum RS. Implicit memory varies across the menstrual cycle: estrogen effects in young women. Neuropsychologia 2002; 40: 518-29
89. Sherwin BB. Can estrogen keep you smart? Evidence from clinical studies. J Psychiatry Neurosci 1999; 24: 315-21
90. Miles C, Green R, Sanders G, et al. Estrogen and memory in a transsexual population. Horm Behav 1998; 34: 199-208
91. Ross JL, Roeltgen D, Feuillan P, et al. Use of estrogen in young girls with Turner syndrome: effects on memory. Neurology 2000; 54: 164-70
92. Sherwin BB, Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996; 81: 2545-9
93. Vroon P, van Amerongen A, de Vries H. Smell: the secret seducer. New York: Farrar, Straus and Giroux, 1997
94. Eberling JL, Wu C, Haan MN, et al. Preliminary evidence that estrogen protects against age-related hippocampal atrophy. Neurobiol Aging 2003; 24: 725-32
95. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999; 281: 1197-202
96. Pelligrino DA, Galea E. Estrogen and cerebrovascular physiology and pathophysiology. Jpn J Pharmacol. 2001 Jun; 86 (2): 137-58
97. Hosoda T, Nakajima H, Honjo H. Estrogen protects neuronal cells from amyloid beta-induced apoptotic cell death. Neuroreport 2001; 12: 1965-70
98. Zhang L, Rubinow DR, Xaing G, et al. Estrogen protects against beta-amyloid-induced neurotoxicity in rat hippocampal neurons by activation of Akt. Neuroreport 2001; 12: 1919-23
99. Petanceska SS, Nagy V, Frail D, et al. Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain. Neurology 2000; 54: 2212-7
100. Smith JD, Levin JA. Estrogen and ApoE: drug discovery implications. In: Fillit HM, O'Connell AW, editors. Drug discovery and development for Alzheimer's disease 2000. New York: Springer, 2002: 129-36
101. Zheng H, Xu H, Uljon SN, et al. Modulation of Aβ peptides by estrogen in mouse models. J Neurochem 2002; 80: 191-6
102. Gandy S, Almeida OP, Fonte J, et al. Chemical andropause and amyloid-β peptide. JAMA 2001; 285: 2195-6
103. Scorer CA. Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease. Drug Discov Today 2001; 6: 1207-19
104. Schumacher M, Weill-Engerer S, Liere P, et al. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog Neurobiol 2003; 71: 3-29
105. Haskell SG, Richardson ED, Horwitz RI. The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. J Clin Epidemiol 1997; 50: 1249-64
106. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517-21
107. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998; 50: 996-1002
108. Marder K, Tang M-X, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998; 50: 1141-3
109. Leranth C, Roth RH, Elswoth JD, et al. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 2000; 20: 8604-9
110. Schneider LS, Farlow MR, Henderson VW, et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996; 46: 1580-4
111. Manly JJ, Merchant CA, Jacobs DM, et al. Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 2000; 54: 833-7
112. Senanarong V, Vannasaeng S, Poungvarin N, et al. Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. Arch Neurol 2002; 59: 385-9
113. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001; 57: 605-12
114. Bush T. Hormone therapy and breast cancer: a differing view, 1998. Presented at the University of Kansas School of Medicine; 1998 Nov 5; Wichita (KA).
115. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291: 2947-58
116. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291: 2959-68
117. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651-62
118. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2663-72
119. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 1998; 217: 6-16
120. Bhavnani BR. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol 2003; 85: 473-82
121. Steingold KA, Cefalu W, Pardridge W, et al. Enhanced hepatic extraction of estrogens used for replacement therapy. J Clin Endocrinol Metab 1986; 62: 761-6
122. Sherwin BB. Surgical menopause, estrogen, and cognitive function in women: what do the findings tell us? Ann N Y Acad Sci 2005; 1052: 3-10
123. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001; 63: 29-60
124. Wise PM, Dubal DB, Rau SW, et al. Are estrogens protective or risk factors in brain injury and neurodegeneration? Reevaluation after the Women's Health Initiative. Endocr Rev 2005; 26: 308-12
125. Amantea D, Russo R, Bagetta G, et al. From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens. Pharmacol Res 2005; 52: 119-32
126. Singer CA, Figueroa-Masot XA, Batchelor RH, et al. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 1999; 19: 2455-63
127. Cardona-Gomez GP, Mendez P, DonCarlos LL, et al. Interactions of estrogens and insulin-like growth factor-I in the brain: implications for neuroprotection. Brain Res Brain Res Rev 2001; 37: 320-34
128. Behl C, Widmann M, Trapp T, et al. 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 1995; 216: 473-82
129. Simpkins JW, Rajakumar G, Zhang Y-Q, et al. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg 1997; 87: 724-30
130. Dubal DB, Kashon ML, Pettigrew LC, et al. Estradiol protects against ischemic injury. J Cereb Blood Flow Metab 1998; 18: 1253-8
131. Culmsee C, Vedder H, Ravati A, et al. Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab 1999; 19: 1263-9
132. Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab 2000; 20: 631-52
133. Dubal DB, Zhu H, Yu J, et al. Estrogen receptor α, not β, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci U S A 2001; 98: 1952-7
134. Vegeto E, Belcredito S, Etteri S, et al. Estrogen receptor-α mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci U S A 2003; 100: 9614-9
135. Goldstein GW, Betz AL. The blood-brain barrier. Sci Am 1986; 255 (3): 74-83
136. Bradbury MWB, editor. Physiology and pharmacology of the blood-brain barrier. Berlin: Springer, 1992
137. Begley DJ. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 1996; 48: 136-46
138. Buchwald P, Bodor N. Octanol-water partition: searching for predictive models. Curr Med Chem 1998; 5: 353-80
139. Abbott NJ. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov Today Technol 2004; 1: 407-16
140. Bodor N, Buchwald P. Brain-targeted delivery: experiences to date. Am J Drug Deliv 2003; 1: 13-26
141. Bodor N, Brewster ME. Problems of delivery of drugs to the brain. Pharmacol Ther 1983; 19: 337-86
142. Bodor N, Brewster ME. Chemical delivery systems. In: Juliano RL, editor. Targeted drug delivery. Berlin: Springer, 1991: 231-84
143. Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 1999; 36: 229-54
144. Bodor N, Buchwald P. Retrometabolism-based drug design and targeting. In: Abraham DJ, editor. Burger's medicinal chemistry and drug discovery. Vol. 2. Drug discovery and drug development. 6th ed. New York: Wiley, 2003: 533-608
145. Bodor N, Buchwald P. Targeting of neuropharmaceuticals by chemical delivery systems. In: Dermietzel R, Spray DC, Needergard M, editors. Blood-brain interfaces: from ontogeny to artificial barriers. Weinheim: Wiley-VCH, 2006: 463-500
146. Janocko L, Lamer JM, Hochberg RB. The interaction of C-17 esters of estradiol with the estrogen receptor. Endocrinology 1984; 114: 1180-6
147. Brewster ME, Druzgala PJ, Anderson WR, et al. Efficacy of a 3-substituted versus 17-substituted chemical delivery system for estradiol brain targeting. J Pharm Sci 1995; 84: 38-43
148. Brewster ME, Bartruff MSM, Anderson WR, et al. Effect of molecular manipulation on the estrogenic activity of a brain-targeting estradiol chemical delivery system. J Med Chem 1994; 37: 4237-44
149. Brewster ME, Estes KE, Loftsson T, et al. Improved delivery through biological membranes. XXXI. Solubilization and stabilization of an estradiol chemical delivery system by modified β-cyclodextrins. J Pharm Sci 1988; 77: 981-5
150. Pitha J, Pitha J. Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. J Pharm Sci 1985; 74: 987-90
151. Pitha J, Milecki J, Fales H, et al. Hydroxypropyl-β-cyclodextrin: preparation and characterization, effects on solubility of drugs. Int J Pharm 1986; 29: 73-82
152. Yoshida A, Arima H, Uekama K, et al. Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrins. Int J Pharm 1988; 46: 217-22
153. Brewster ME, Estes KS, Bodor N. An intravenous toxicity study of 2-hydroxypropyl-β-cyclodextrin, a useful drug solubilizer, in rats and monkeys. Int J Pharm 1990; 59: 231-43
154. Bodor N, McCornack J, Brewster ME. Improved delivery through biological membranes. XXII. Synthesis and distribution of brain-selective estrogen delivery systems. Int J Pharm 1987; 35: 47-59
155. Mullersman G, Derendorf H, Brewster ME, et al. High performance liquid chromatographic assay of a central nervous system (CNS)-directed estradiol chemical delivery system and its application after intravenous administration in rats. Pharm Res 1988; 5: 172-7
156. Sarkar DK, Friedman SJ, Yen SSC, et al. Chronic inhibition of hypothalamic-pituitary-ovarian axis and body weight gain by brain-directed delivery of estradiol-17β in female rats. Neuroendocrinology 1989; 50: 204-10
157. Rahimy MH, Simpkins JW, Bodor N. Dose and time-course evaluation of a redox-based estradiol-chemical delivery system for the brain: I. tissue distribution. Pharm Res 1990; 7: 1061-7
158. Estes KS, Keuth V, Dietzel K, et al. A redox-based chemical delivery system that enhances estradiol distribution to the brain: disposition studies in the rat. Pharm Res 1991; 8: 1180-5
159. Dietzel K, Keuth V, Estes KS, et al. A redox-based system that enhances delivery of estradiol to the brain: pharmacokinetic evaluation in the dog. Pharm Res 1990; 7: 879-83
160. Estes KS, Brewster ME, Simpkins JW, et al. A novel redox system for CNS-directed delivery of estradiol causes sustained LH suppression in castrate rats. Life Sci 1987; 40: 1327-34
161. Simpkins JW, McCornack J, Estes KS, et al. Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion. J Med Chem 1986; 29: 1809-12
162. Estes KS, Brewster ME, Bodor NS. A redox system for brain targeted estrogen delivery causes chronic body weight decrease in rats. Life Sci 1988; 42: 1077-84
163. Simpkins JW, Anderson WR, Dawson R, et al. Chronic weight loss in lean and obese rats with a brain-enhanced chemical delivery system for estradiol. Physiol Behav 1988; 44: 573-80
164. Simpkins JW, Anderson WR, Dawson R, et al. Effects of a brain-enhanced chemical delivery system for estradiol on body weight and food intake in intact and ovariectomized rats. Pharm Res 1989; 6: 592-600
165. Rahimy MH, Bodor N, Simpkins JW. Suppression of plasma testosterone and prostate carcinoma size by a redox-based, brain-targeted estrogen delivery system in the rat. Prostate 1993; 23: 79-90
166. Rahimy MH, Bodor N, Simpkins JW. Effects of a brain-enhanced estrogen delivery system on tail-skin temperature of the rat: implications for menopausal hot flush. Maturitas 1991; 13: 51-63
167. Brewster ME, Simpkins JW, Bodor N. Brain-targeted delivery of estrogens. Rev Neurosci 1990; 2: 241-85
168. Libertun C, Orias R, McCann SM. Biphasic effect of estrogen on the sensitivity of the pituitary to luteinizing hormone-releasing factor (LRF). Endocrinology 1974 Apr; 94 (4): 1094-100
169. Henderson SR, Baker C, Fink G. Oestradiol-17beta and pituitary responsiveness to luteinizing hormone releasing factor in the rat: a study using rectangular pulses of oestradiol-17beta monitored by non-chromatographic radioimmunoassay. J Endocrinol 1977 Jun; 73 (3): 441-53
170. Simpkins JW, Rahimy MH, Bodor N. A brain-enhanced delivery system for gonadal steroids: implication for neurogenerative diseases. In: Meyer EM, Simpkins JW, Yamamoto J, editors. Novel approaches to the treatment of Alzheimer's disease. New York: Plenum Press, 1989: 197-212
171. Rabbani O, Panickar KS, Rajakumar G, et al. 17 β-estradiol attenuates fimbrial lesion-induced decline of ChAT-immunoreactive neurons in the rat medial septum. Exp Neurol 1997; 146: 179-86
172. Brewster ME, Estes KS, Perchalski R, et al. A dihydropyridine conjugate which generates high and sustained levels of the corresponding pyridinium salt in the brain does not exhibit neurotoxicity in cynomolgus monkeys. Neurosci Lett 1988; 87: 277-82
173. Howes J, Bodor N, Brewster ME, et al. A pilot study with PR-63 in postmenopausal volunteers [abstract no. 181]. J Clin Pharmacol 1988; 28: 951
174. Estes KS, Dewland PM, Brewster ME, et al. A redox-based chemical delivery system (CDS) applied to estradiol. Pharm Ztg Wiss 1991; 136: 153-8
175. Estes KS, Brewster ME, Bodor N. Evaluation of an estradiol chemical delivery system (CDS) designed to provide enhanced and sustained hormone levels in the brain. Adv Drug Deliv Rev 1994; 14: 167-75
176. Howes J, Brewster M, Harris A, et al. Buccal and parenteral clinical evaluation of a brain-targeting estradiol chemical delivery system (E2-CDS). Clin Pharmacol Ther 1995; 57: 172
177. Brewster ME, Howes J, Griffith W, et al. Intravenous and buccal 2-hydroxypropyl-β-cyclodextrin formulations of E2-CDS: phase I clinical trials. Proceedings of the 8th International Cyclodextrins Symposium; 1996 Mar 30-Apr 2; Paris. Paris: Editions de Sante, 1996
178. 2CDS in postmenopausal women. Proceedings of the North American Menopause Society, 14th Annual Meeting; 2003 Sep 17-19; Miami (FL).
179. 2CDS-Estredox™) in postmenopausal women. Proceedings of the North American Menopause Society, 15th Annual Meeting; 2004 Oct 6-9; Washington, DC.